热门减肥药司美格鲁肽可致失明?千亿市场生变 诺和诺德、礼来慌了

蓝鲸财经
14 Feb

蓝鲸新闻2月14日讯GLP-1RAs在糖尿病和肥胖症治疗中应用日益广泛,但其风险性也越来越受到重视。根据近日发表在《美国医学会杂志-眼科学》(JAMA OphthalmologyTrusted Source)上的刊文指出,2023年,近2%的美国人口获得了司美格鲁肽(semaglutide,一种胰高血糖素样肽-1受体激动剂(GLP-1RA),主要用于治疗2型糖尿病和肥胖)的处方,最近有人担心这种...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10